Revenue grew 105% year-over-year to $2.2 million, driven by expanded adoption of the first-generation LungFit PH system across more than 45 hospitals.

Customer retention exceeds 90% with over half of the current customer base secured under multiyear agreements, providing a stable foundation for future Gen II conversion.

The commercial strategy has shifted toward high-priority hospitals that are likely to adopt Gen I immediately and expand usage once the transport-compatible Gen II system is approved.

The divestiture of the NeuroNOS subsidiary to XTL Biopharmaceuticals allows the company to focus resources on core commercial operations while retaining a 19.9% equity stake and up to $31.5 million in milestones.

Operating expenses were reduced by 36% year-over-year, reflecting disciplined cost-cutting in SG&A and the completion of major R&D spending for the Gen II regulatory filing.

International expansion reached 40 countries, with management noting a transition from initial device placement to recurring revenue from accessory reorders.

FDA decision for the second-generation LungFit PH system is expected before the end of calendar 2026, subject to regulatory review and contract manufacturer inspections.

The Gen II system is designed to expand the addressable market by introducing compatibility with air and ground transport, a key feature requested by clinicians.

Management anticipates that overall cash burn will continue to decline as revenue grows, though inventory building for the Gen II launch may temporarily impact cash flow.

Current capital resources, including recent equity financing and credit lines, are projected to provide a cash runway into calendar year 2027 and potentially to profitability.

Phase Ib oncology studies for Beyond Cancer remain a strategic priority, but full funding commitment is contingent on reaching a more comfortable path to profitability.

Completed a $5 million financing in January 2026 and secured a $32 million equity line of credit to support commercial readiness.

Achieved the first commercial sale to a VA Medical Center via partner TrillaMed, establishing a foothold in the largest U.S. healthcare network.

Gen II system reliability testing has surpassed the 3,000-hour mark, which is expected to triple the service interval compared to Gen I and improve long-term gross margins.

The 1-for-20 reverse stock split effective July 14, 2025, is reflected in the reported net loss of $0.85 per share.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management clarified that products are offered through the ECAD catalog, allowing direct access for VA customers outside of traditional RFP processes.

The initial sale to a single VA hospital serves as a critical entry point for broader adoption across the entire federal network.

The typical sales cycle remains 6 to 9 months, though highly organized hospitals can complete evaluations in 4 to 5 months.

Management is mitigating 'wait-and-see' behavior by focusing Gen I sales on non-transport clinical settings, while positioning Gen II specifically for transport-heavy requirements.

Management expects the Gen II system to improve gross margins, driven by significantly lower service requirements as the service interval increases from 10 months to at least 30 months.

Gen I margins are expected to stabilize in the 50% to 60% range, depending on final market pricing dynamics.

The primary gating factor is the completion of work at the contract manufacturer to allow for a final FDA inspection.

Management expressed high confidence in the timeline, stating there are no major regulatory hurdles and all reliability testing requirements have already been met.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.